文献速递肿瘤 PET/CT核素与放射性配体治疗

利用PET成像评估叶酸受体α抗体偶联药物靶向治疗

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate.
PubMed 文献 · EJNMMI Res · 2018-08-28

本研究在临床前开发了靶向叶酸受体α(FRα)的89Zr标记抗体探针[89Zr]Zr-DFO-M9346A,在KB和OV90皮下移植瘤中显示良好肿瘤摄取,其血液半衰期与治疗性ADC [131I]-IMGN853相当,为FRα靶向治疗的伴随诊断PET成像奠定基础。

要点

  • DFO-M9346A经89Zr标记,标记产率85.7±5.7%,放射化学纯度98.0±0.7%,比活度3.08±0.43 mCi/mg。
  • KB和OV90移植瘤中[89Zr]Zr-M9346A肿瘤摄取分别为45.8±29.0 %IA/g和26.1±7.2 %IA/g,肾脏摄取分别为4.5±1.2 %IA/g和4.3±0.7 %IA/g。
  • [89Zr]Zr-M9346A与[131I]-IMGN853血液半衰期相当,支持其作为ADC治疗的伴随诊断PET探针。

原文

BACKGROUND: The folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), IMGN853, shows great antitumor activity against FRα-expressing tumors in vivo, but patient selection and consequently therapy outcome are based on immunohistochemistry. The aim of this study is to develop an antibody-derived immuno-PET imaging agent strategy for targeting FRα in ovarian cancer as a predictor of treatment success. METHODS: We developed [89Zr]Zr-DFO-M9346A, a humanized antibody-based radiotracer targeting tumor-associated FRα in the preclinical setting. [89Zr]Zr-DFO-M9346A's binding ability was tested in an in vitro uptake assay using cell lines with varying FRα expression levels. The diagnostic potential of [89Zr]Zr-M9346A was evaluated in KB and OV90 subcutaneous xenografts. Following intravenous injection of [89Zr]Zr-DFO-M9346A (~90 μCi, 50 μg), PET imaging and biodistribution studies were performed. We determined the blood half-life of [89Zr]Zr-DFO-M9346A and compared it to the therapeutic, radioiodinated ADC [131I]-IMGN853. Finally, in vivo studies using IMG853 as a therapeutic, paired with [89Zr]Zr-DFO-M9346A as a companion diagnostic were performed using OV90 xenografts. RESULTS: DFO-M9346A was labeled with Zr-89 at 37 °C within 60 min and isolated in labeling yields of 85.7 ± 5.7%, radiochemical purities of 98.0 ± 0.7%, and specific activities of 3.08 ± 0.43 mCi/mg. We observed high specificity for binding FRα positive cells in vitro. For PET and biodistribution studies, [89Zr]Zr-M9346A displayed remarkable in vivo performance in terms of excellent tumor uptake for KB and OV xenografts (45.8 ± 29.0 %IA/g and 26.1 ± 7.2 %IA/g), with low non-target tissue uptake in other organs such as kidneys (4.5 ± 1.2 %IA/g and 4.3 ± 0.7 %IA/g). A direct comparison of the blood half life of [89Zr]Zr-M9346A and [131I]-IMGN853 corroborated the equivalency of the radiopharmaceutical and the ADC, paving the way for a companion PET imaging study. CONCLUSIONS: We developed a new folate receptor-targeted 89Zr-labeled PET imaging agent with excellent pharmacokinetics in vivo. Good tumor uptake in subcutaneous KB and OV90 xenografts were obtained, and ADC therapy studies were performed with the precision predictor.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Brand C, Sadique A, Houghton JL, et al. Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate. EJNMMI Res. 2018. PMID: 30155674. doi:10.1186/s13550-018-0437-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。